Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
267 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape. Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 11, 50 and 14 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 4, 13 and 4 molecules, respectively.Respiratory Syncytial Virus (RSV) Infections. Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 Introduction 6 Respiratory Syncytial Virus (RSV) Infections Overview 7 Therapeutics Development 8 Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies 10 Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes 14 Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance 15 Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies 18 Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes 23 Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 25 Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 85 Drug Profiles 95 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 237 Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 242 Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 243 Appendix 254
List of Tables Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2016 20 Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2016 21 Number of Products under Development by Companies, H2 2016 22 Number of Products under Development by Companies, H2 2016 (Contd..1) 23 Number of Products under Development by Companies, H2 2016 (Contd..2) 24 Number of Products under Development by Companies, H2 2016 (Contd..3) 25 Number of Products under Investigation by Universities/Institutes, H2 2016 26 Comparative Analysis by Late Stage Development, H2 2016 27 Comparative Analysis by Clinical Stage Development, H2 2016 28 Comparative Analysis by Early Stage Development, H2 2016 29 Products under Development by Companies, H2 2016 30 Products under Development by Companies, H2 2016 (Contd..1) 31 Products under Development by Companies, H2 2016 (Contd..2) 32 Products under Development by Companies, H2 2016 (Contd..3) 33 Products under Development by Companies, H2 2016 (Contd..4) 34 Products under Investigation by Universities/Institutes, H2 2016 35 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA, H2 2016 37 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H2 2016 38 Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H2 2016 39 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H2 2016 40 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 41 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H2 2016 42 Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H2 2016 43 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aviragen Therapeutics, Inc., H2 2016 44 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H2 2016 45 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H2 2016 46 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H2 2016 47 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Curevac AG, H2 2016 48 Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies S.A., H2 2016 49 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H2 2016 50 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016 51 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec, Inc., H2 2016 52 Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 53 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gene Techno Science Co., Ltd., H2 2016 54 Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H2 2016 55 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H2 2016 56 Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 57 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Globavir Biosciences, Inc., H2 2016 58 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H2 2016 59 Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H2 2016 60 Respiratory Syncytial Virus (RSV) Infections - Pipeline by ILiAD Biotechnologies, LLC, H2 2016 61 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ilyang Pharmaceutical Co., Ltd, H2 2016 62 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine Inc, H2 2016 63 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 64 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H2 2016 65 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 66 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H2 2016 67 Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience S.A., H2 2016 68 Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune LLC, H2 2016 69 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H2 2016 70 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H2 2016 71 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H2 2016 72 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mymetics Corporation, H2 2016 73 Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H2 2016 74 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 75 Respiratory Syncytial Virus (RSV) Infections - Pipeline by NeuClone Pty Ltd, H2 2016 76 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H2 2016 77 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H2 2016 78 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences, Inc., H2 2016 79 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H2 2016 80 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 81 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H2 2016 82 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech, H2 2016 83 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016 84 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 85 Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H2 2016 86 Respiratory Syncytial Virus (RSV) Infections - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 87 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Themis Bioscience GmbH, H2 2016 88 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Trellis Bioscience, Inc., H2 2016 89 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc., H2 2016 90 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart Inc, H2 2016 91 Respiratory Syncytial Virus (RSV) Infections - Pipeline by VaxInnate Corporation, H2 2016 92 Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc, H2 2016 93 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H2 2016 94 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra, Inc., H2 2016 95 Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech, Inc., H2 2016 96 Assessment by Monotherapy Products, H2 2016 97 Assessment by Combination Products, H2 2016 98 Number of Products by Stage and Target, H2 2016 100 Number of Products by Stage and Mechanism of Action, H2 2016 102 Number of Products by Stage and Route of Administration, H2 2016 104 Number of Products by Stage and Molecule Type, H2 2016 106 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2016 249 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H2 2016 250 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H2 2016 251 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..3), H2 2016 252 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..4), H2 2016 253 Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H2 2016 254
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
